The double blinding of drug trials to prevent bias deprives physicians of information they need in order to comply with their duty to treat patients and do them no harm. This ethical dilemma can be ameliorated with a standard statistical method known as posterior analysis. The clinical researcher can use posterior analysis to calculate the probability that a patient in a double-blinded drug trial is in the placebo group, based on the patient's clinical status. The clinician can also calculate the probability that the drug is safe and efficacious, as compared with the placebo, without breaking the code.
Clifford DBThe somatosensory system in pain. In: Pearlman AL, Collins RC, eds. Neurological pathophysiology. 3rd ed. New York: Oxford University Press, 1984;82-3.
3.
Fairchild CJ, Rush AJ, Vasavada N., et al. Which depressions respond to placebo? Psychiatry Res.1986;18:217-26.
4.
Dobrilla G.Placebo in the evaluation of antiulcer drugs. Int J Tissue React.1983;5:329-37.
5.
Fisher B.Clinical trials for the evaluation of cancer therapy. Cancer.1984;54:2609-17.
6.
Committee of Principal Investigators.Report from a co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J.1978 ;40:1069-118.
7.
Rosner F.The ethics of randomized clinical trials. Am J Med.1987;82:283-90.
8.
Howard J., Friedman L.Protecting the scientific integrity of a clinical trial: some ethical dilemmas . Clin Pharmacol Ther.1981;29:561-9.
Rudicel S., Esdaile J.The randomized clinical trial in orthopaedics : obligation or option? J Bone Joint Surg.1985;67:1284-93.
11.
May GS, DeMets DL, Friedman LM, et al. The randomized clinical trial: bias in analysis. Circulation.1981;64:669-73.
12.
Goldman J., Katz MDInconsistency and institutional review boards. JAMA.1982;248:197-202.
13.
Clemens JD, Horwitz RILongitudinal methods for evaluating therapy. Biomed Pharmacother.1984;38:440-3.
14.
Gross PACollection of data documenting risk factors: safeguards in conducting case-control studies. Am J Med.1984;7628-33.
15.
Ney PG, Collins C., Spensor C.Double blind: double talk or are there ways to do better research. Med Hypotheses.1986;21:119-26.
16.
Horwitz RIComplexity and contradiction in clinical trial research. Am J Med.1987;82:498-510.
17.
Kadane JBProgress toward a more ethical method for clinical trials. J Med Philos.1986;11:385-404.
18.
Wulff HRRational diagnosis and treatment. J Med Philos.1986;11:297-315.
19.
Mazur DJInformed consent: court viewpoints and medical decision making. Med Decis Making.1986;6:224-30.
20.
Howard JM, DeMets D.How informed is informed consent? The BHAT experience. Controlled Clin Trials.1981;2:287-303.
21.
Haegerstam G., Huitfeldt B., Nilsson BS, et al. Placebo in clinical drug trials—a multidisciplinary review. Methods Find Exp Clin Pharmacol.1982;4:261-78.
22.
Marquis D.An argument that all prerandomized clinical trials are unethical. J Med Philos.1986;11:367-83.
23.
Gifford F.The conflict between randomized clinical trials and the therapeutic obligation . J Med Philos.1986;11:347-66.
24.
Kopelman L.Consent and randomized clinical trials: are there moral or design problems? J Med Philos.1986;11:317-45.
25.
Levine RJEthics and regulation of clinical research. 2nd ed. Baltimore: Urban and Schwarzenberg, 1986.
26.
Allen ADScientific versus judicial fact finding in the United States. IEEE Trans Systems Man Cybern.1972;SMC-2:548-50. Reviewed in: Psychology Today(Newsline), April 1973 ; Am Bar Assoc J, February 1974;234-5.
27.
Physicians' desk reference. 40th ed. Oradell, NJ: Medical Economics, 1986:1583.
